Payment overview · 2025
General Payments
$405.97
17 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Dwight Floyd, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MARYVILLE, TN · NPI 1861470809
Verified facts
What the public records show
CMS Open Payments records show Michael Dwight Floyd, M.D. received $405.97 in general payments during 2025 across 17 reported records.
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 383 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $121.73 | 30.0% | 4 | 2025 |
| Tetraphase Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.12 | 16.8% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $67.63 | 16.7% | 3 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $65.67 | 16.2% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $45.34 | 11.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.48 | 9.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.97 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $121.73 | 4 | 2025 |
Source payment records
|
|||||
| XERAVA Normalized: xerava |
Drug | Tetraphase Pharmaceuticals, Inc. | $68.12 | 3 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $65.67 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $47.05 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $45.34 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 383 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
383 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1392 | 54 |
| Eliquis | Apixaban | 383 | 25 |
| Allopurinol | Allopurinol | 254 | 37 |
| Gemtesa | Vibegron | 246 | 11 |
| Sertraline Hcl | Sertraline Hcl | 224 | 28 |
| Potassium Chloride | Potassium Chloride | 214 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 34 |
| Buspirone Hcl | Buspirone Hcl | 135 | 27 |
| Mirtazapine | Mirtazapine | 133 | 20 |
| Carvedilol | Carvedilol | 122 | 21 |
| Donepezil Hcl | Donepezil Hcl | 122 | 17 |
| Divalproex Sodium | Divalproex Sodium | 120 | 17 |
| Xarelto | Rivaroxaban | 117 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 23 |
| Baclofen | Baclofen | 113 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 106 | suppressed |
| Furosemide | Furosemide | 103 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 30 |
| Levetiracetam | Levetiracetam | 93 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 19 |
| Trazodone Hcl | Trazodone Hcl | 89 | 12 |
| Spironolactone | Spironolactone | 83 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 19 |
| Bumetanide | Bumetanide | 80 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 75 | suppressed |
| Lisinopril | Lisinopril | 74 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 27 |
| Losartan Potassium | Losartan Potassium | 63 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 43 | suppressed |
| Prednisone | Prednisone | 43 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 12 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 11 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Nyamyc | Nystatin | 28 | 12 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 22 |
| Linzess | Linaclotide | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 16 |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | 13 |
| Fluconazole | Fluconazole | 21 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | 11 |
| Glipizide | Glipizide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.97 · 17 records | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | AVYCAZ, CAMZYOS, DALVANCE, ELIQUIS, JOURNAVX, LifeVest, TEFLARO, XERAVA, ZEVTERA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error